Canagliflozin and myocardial oxidative stress: SGLT1 inhibition takes centre stage

This editorial refers to ‘Effects of canagliflozin on human myocardial redox signalling: clinical implications’, by H. Kondo et al., http://dx.doi:10.1093/eurheartj/ehab420. Sodium–glucose co-transporter type 2 inhibitors (SGLT2is), also known as gliflozins, are a recently discovered class of oral antidiabetic drugs.1 SGLT2is promote urinary glucose excretion through inhibition of SGLT2 and SGLT1, which are responsible for ∼90% and 10% of...